Get the Stockscreener App
37.54
1.62%
0.60
After Hours:
37.60
0.06
+0.16%
Royalty Pharma Plc stock is traded at $37.54, with a volume of 3.77M.
It is up +1.62% in the last 24 hours and up +6.41% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$36.94
Open:
$36.83
24h Volume:
3.77M
Relative Volume:
1.00
Market Cap:
$16.23B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.34
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
+0.75%
1M Performance:
+6.41%
6M Performance:
+14.38%
1Y Performance:
+39.04%
1-Day Range:
$36.67
$37.62
1-Week Range:
$35.91
$37.62
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.54 | 15.97B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Historical volatility pattern of Royalty Pharma plc visualized2025 Bull vs Bear & Stock Timing and Entry Methods - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
What the charts say about Royalty Pharma plc today2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
How Royalty Pharma plc (RPD) stock performs in easing cycles2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
28,646 Shares in Royalty Pharma PLC $RPRX Bought by Nisa Investment Advisors LLC - MarketBeat
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks - MSN
What MACD signals say about Royalty Pharma plcQuarterly Growth Report & Expert Curated Trade Setups - newser.com
Using Python tools to backtest Royalty Pharma plc strategiesMarket Trend Report & Stock Portfolio Risk Control - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveWall Street Watch & Risk Managed Investment Signals - newser.com
Royalty Pharma (NASDAQ:RPRX) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
What drives Royalty Pharma plc stock priceMarket Sentiment Extremes & Low Risk Trading Ideas - earlytimes.in
Royalty Pharma PLC $RPRX Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Detecting support and resistance levels for Royalty Pharma plcJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com
Is Royalty Pharma plc stock a top momentum play2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next yearMarket Trend Summary & High Conviction Buy Zone Alerts - newser.com
Is Royalty Pharma plc reversing from oversold territoryJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Impact Partnership Wealth LLC Purchases 12,329 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What’s the recovery path for long term holders of Royalty Pharma plcTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
What indicators show strength in Royalty Pharma plcJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Why retail investors pile into Royalty Pharma plc stockQuarterly Trade Report & AI Forecasted Entry and Exit Points - newser.com
Why Royalty Pharma plc (RPD) stock could rally stronglyQuarterly Market Review & Community Consensus Trade Signals - newser.com
Is Royalty Pharma plc stock a safe investment in uncertain marketsGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
Is Royalty Pharma plc (RPD) stock a buy during volatile marketsJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com
Royalty Pharma plc (RPRX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Whalen Wealth Management Inc. Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Experiences Evaluation Revision Amidst Mixed Market Indicators - Markets Mojo
Royalty Pharma (RPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):